---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-21-036567"
form_type: "8-K"
ticker: "SIGA"
cik: "0001010086"
company_name: "SIGA TECHNOLOGIES INC"
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T12:30:09.791038+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SIGA reports Q3 revenue drop to $4.8M, net loss of $3.1M; secures $113M BARDA order for Q4

## Summary
- Total revenues $4.8M in Q3 2021 vs $44.3M in Q3 2020; net loss $3.1M ($0.04 diluted loss) vs net income $24.2M ($0.31 diluted EPS).
- Nine months 2021: revenues $18.3M, net loss $3.8M ($0.05 diluted loss) vs prior year revenues $87.2M, net income $36.2M ($0.45 diluted EPS).
- BARDA exercised procurement option for oral TPOXX worth ~$113M; delivery targeted for Q4 2021, nearly 30% delivered in October.
- Board authorized new $50M share repurchase program through Dec 2023; repurchased 1.1M shares for $7.1M in Q3.
- International sales nine months $13M, >4x increase vs 2020; working on new foreign order similar to Canada initial orders.

## SEC filing metadata
- accession: 0001140361-21-036567
- form_type: 8-K
- ticker: SIGA
- cik: 0001010086
- company_name: SIGA TECHNOLOGIES INC
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1010086/000114036121036567/0001140361-21-036567-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1010086/000114036121036567/brhc10030432_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-21-036567
- JSON: https://secwatch.observer/filing/0001140361-21-036567.json
- Plain text: https://secwatch.observer/filing/0001140361-21-036567.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.